TABLE 2.
Cyp51A profile for 18 Aspergillus fumigatus and Aspergillus terreus isolates with decreased susceptibility from 15 CF patients at the two referral centers in Denmark.
| Species/patient IDa | Susceptibility classificationb | Cyp51A profile |
| A. fumigatus | ||
| AUH-1 | Intermediate | Wildtype |
| AUH-2 | Resistant | TR34/L98H |
| RH-1 | Intermediate | Wildtype |
| RH-2 | Intermediate | Wildtype |
| Resistant | Wildtype | |
| RH-3 | Resistant | Wildtype |
| RH-4 | Resistant | TR34/L98H/S297T/F495I |
| RH-5 | Resistant | TR343/L98H |
| Resistant | TR34/L98H | |
| RH-6 | Resistant | TR34/L98H |
| RH-7 | Resistant | TR34/L98H |
| RH-8 | Resistant | M220R |
| RH-9 | Resistant | M220K |
| RH-10 | Resistant | M220K |
| A. terreus | ||
| AUH-3 | Resistant | |
| RH-11 | Resistant | M217I |
| Intermediate | Y491H | |
| RH-12 | Resistant | G51A |
aAUH, Aarhus University Hospital, RH, Rigshospitalet. bAccording to EUCAST clinical breakpoints for antifungals v 9.0, for A. fumigatus an isolate was considered resistant when MIC for ITR was >2 mg/L, POS > 0.25 mg/L and VOR > 2 mg/L. It was considered intermediate when MIC for itraconazole was 2 mg/L, posaconazole 0.25 mg/L and voriconazole 2 mg/L.